TL;DR
Prime made for students and young adults
- Fast, free delivery for dorm and study essentials
- Prime Video and Amazon Music included
- Member-only deals
A U.S. policy released Nov. 5 requires federally funded scientists to buy synthetic nucleic acids and new benchtop synthesis equipment from approved suppliers. The suppliers must verify customers and screen orders, replacing a voluntary system in stages over 340 days. Experts say the policy could make misuse harder but note gaps in its scope, screening thresholds and enforcement resources.
The U.S. government has released a policy requiring federally funded scientists who make or manipulate DNA to order synthetic nucleic acids and new benchtop synthesis equipment from approved suppliers. The suppliers must verify customers’ identities and screen orders for sequences that could encode dangerous pathogens or toxins, replacing a voluntary system as the requirements take effect in stages over 340 days.
The National Policy for Nucleic Acid Synthesis Screening, released Nov. 5, applies to government-funded researchers and sets requirements for vendors supplying synthetic nucleic acids and newly built benchtop synthesis equipment. The policy calls for screening orders and checking customer identities; it does not apply to every researcher or every DNA supplier. The source report says implementation will be phased in, but does not provide a detailed schedule for each requirement.
The policy formalizes screening practices that some suppliers already followed voluntarily. U.S. guidelines issued in 2010 recommended that synthetic biology companies vet customers and screen orders for potentially dangerous DNA. Many companies complied, including members of the International Gene Synthesis Consortium, an industry group described in the source report as responsible for most DNA synthesis worldwide. The new policy shifts the requirement for covered researchers from voluntary industry practice to a government-backed purchasing rule.
The report identifies several limits. The policy requires screening for sequences 50 base pairs or longer, while MIT biosecurity expert Kevin Esvelt says shorter fragments could be combined to make a longer sequence. It also covers newly built synthesis equipment, not the many machines already in use. The National Institute of Standards and Technology (NIST) is tasked with helping enforce the policy, but the report says the policy does not necessarily provide additional resources for that work.
How Screening Could Limit Access
DNA synthesis services allow researchers to order sequences online, while benchtop machines let laboratories produce DNA on site. The policy aims to add checks at those points of access, making it harder for a customer to obtain a sequence that could contribute to creating a dangerous pathogen. That matters as concerns grow that advances in technology, including artificial intelligence, could make some biological work easier.
Biosecurity experts interviewed by Science described the policy as a useful but incomplete barrier. Esvelt said screening could make misuse harder, and Stanford researcher Drew Endy called the move from voluntary to verified screening a step forward. But the rules do not cover all researchers, all existing machines or every possible route to manipulating DNA. The policy is therefore one layer of prevention, not a guarantee against bioterrorism.
The limits also matter for public preparedness. Johns Hopkins expert Gigi Gronvall said synthetic-DNA screening is only one tool, and argued that responses to future outbreaks also depend on measures such as vaccine development and hospital readiness. The policy addresses access to particular materials and equipment; it does not by itself establish broader protection from biological threats.
Popular right now
KitchenAid Artisan 5-Qt Tilt Head Stand Mixer, Milkshake
Dyson V15 Detect Cordless Vacuum
Dyson Airwrap i.d. Multi-Styler for Straight and Wavy Hair
As an affiliate, we earn on qualifying purchases.
From Voluntary Guidelines to Rules
Scientists have synthesized DNA for decades, but improvements in technology have made it possible to produce longer sequences that can be assembled into genes or, in some cases, whole bacterial and viral genomes. Researchers commonly order sequences from commercial suppliers. The spread of benchtop synthesizers has also enabled laboratories to make DNA in-house, reducing reliance on outside vendors.
In 2010, the U.S. government issued voluntary guidance recommending that companies check customers and screen orders for sequences of concern. Some industry suppliers adopted those measures, but biosafety groups called for stronger oversight. The Nov. 5 policy creates a requirement for federally funded researchers to use approved suppliers and, according to the report, is being introduced in stages over 340 days. Its scope remains narrower than a universal rule for all U.S. DNA synthesis.
“It’s great, because it does something instead of nothing.”
— Kevin Esvelt, MIT biotechnologist and biosecurity expert
Gaps in Coverage and Enforcement
Several operational details remain unclear in the source report. Esvelt said the policy does not specify in detail how suppliers must verify customers. The report also does not explain how approved suppliers will be designated, how compliance will be checked in practice, or what penalties might apply for violations.
The 50-base-pair screening threshold is another concern raised by experts: Esvelt said fragments shorter than that could potentially be assembled from orders placed with multiple suppliers. The policy also leaves existing benchtop machines outside its equipment requirements, and any trade-in or buy-back programs for older machines are encouraged rather than mandated. It is not clear how much funding NIST or institutional biosafety officers will receive to carry out the added work.
The rules apply to federally funded researchers, not all customers or companies, and are U.S.-focused. The report does not establish how widely suppliers outside the policy’s reach will adopt equivalent screening, or how much the requirements will reduce the risk of deliberate biological misuse.
A 340-Day Rollout Begins
The policy’s requirements are due to take effect in stages over the next 340 days. NIST is expected to play a role in implementation and enforcement, though the report says resources for that work are not guaranteed. Suppliers and federally funded institutions will need to adapt their purchasing and screening processes as the stages proceed.
Questions likely to shape the rollout include how customer identity checks will work, how screening decisions will be reviewed, and what support will be available to institutional biosafety committees and officers. The policy also encourages, but does not require, manufacturers to offer trade-in or buy-back programs for older synthesis machines. The source report does not specify subsequent review dates or whether the rules will later be expanded.
Key Questions
Who must follow the new U.S. policy?
The policy applies to U.S. government-funded researchers who make or manipulate DNA. It requires them to obtain synthetic nucleic acids and new benchtop synthesis equipment from approved suppliers.
What must approved suppliers do?
Suppliers must verify customers’ identities and screen orders for potentially dangerous DNA sequences, including sequences that could encode toxins or pathogens. The report says the policy does not spell out in detail how identity checks must be carried out.
When do the requirements take effect?
The policy was released on Nov. 5, with requirements scheduled to roll out in stages over 340 days. The source report does not give a separate date for each stage.
Does the policy cover all DNA synthesis equipment?
No. The equipment rules apply to newly built benchtop machines, leaving existing machines outside that requirement. The policy encourages manufacturers to offer trade-in or buy-back programs for older equipment but does not require them to do so.
What do experts say the policy does not address?
Experts cited in the report point to short DNA fragments that may fall below the 50-base-pair screening threshold, the limited U.S. and federally funded scope, and other ways to manipulate DNA. They also raised concerns about enforcement funding and support for institutional biosafety staff.
Source: science.org
